AmunBio Overview
- Year Founded
-
2020
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
AmunBio General Information
Description
Operator of a biotechnology company intended to develop next-generation immunotherapies for cancer treatment. The company offers engineered oncolytic viruses that selectively replicate in tumor cells, block immune suppression, and stimulate cancer-fighting immune responses, enabling healthcare providers to treat various cancers with targeted and effective immuno-oncology therapies.
Contact Information
Website
www.amunbio.comCorporate Office
- Seattle, WA
- United States
Corporate Office
- Seattle, WA
- United States
AmunBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | 01-Jul-2021 | Completed | Pre-Clinical Trials |
AmunBio Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3rdEyeBio | Accelerator/Incubator | Minority |
AmunBio FAQs
-
When was AmunBio founded?
AmunBio was founded in 2020.
-
Where is AmunBio headquartered?
AmunBio is headquartered in Seattle, WA.
-
What industry is AmunBio in?
AmunBio’s primary industry is Drug Discovery.
-
Is AmunBio a private or public company?
AmunBio is a Private company.
-
What is AmunBio’s current revenue?
The current revenue for AmunBio is .
-
Who are AmunBio’s investors?
3rdEyeBio has invested in AmunBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process